Cost-effectiveness Analysis of Breast and Lung Cancer- A Review Study

Authors

Dr. Baharul Islam H, Research Scholar
Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, BG Nagar, Mandya-571448, Karnataka, India.
Dr. Rajesh Venkataraman, Professor and Head
Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, BG Nagar, Mandya-571448, Karnataka, India.

Abstract

According to estimation from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries and ranks third or fourth in a further 23 countries. Cancer is a group of more than 100 different and distinctive diseases. Cancer is the second leading cause of death globally and is responsible for about 10 million deaths per year .Various studies have estimated that reduction in treatment costs through early screening detection may be 30% to 100% or more of the cost of screening. The basic cost-effectiveness calculation appears to be simple, choices about units of measurement, definitions of interventions, scope of costs, and prices to be included not only will alter the numerical results but also will affect the interpretation of the cost-effectiveness ratio. If the cost-effectiveness analysis uses number of deaths averted as its measure of health gain, then allocating resources to more cost-effective interventions will avert the most deaths. Cost-effectiveness analysis helps identify neglected opportunities by highlighting interventions that are relatively inexpensive, yet have the potential to reduce the disease burden substantially.